Apr-07-21 Downgrade
Mizuho
Buy → Neutral
$72 → $29
Apr-07-21 Downgrade
H.C. Wainwright
Buy → Neutral
Mar-31-21 Upgrade
BofA Securities
Neutral → Buy
$47
Mar-02-21 Downgrade
Jefferies
Buy → Hold
$75 → $45
Feb-01-21 Initiated
H.C. Wainwright
Buy
$58
Oct-26-20 Initiated
Raymond James
Underperform
Jul-10-20 Resumed
Stifel
Buy
$71
May-01-20 Initiated
Cowen
Market Perform
$40
Apr-27-20 Initiated
BofA/Merrill
Neutral
$45
May-29-19 Resumed
Goldman
Neutral
May-10-19 Downgrade
William Blair
Outperform → Mkt Perform
Apr-12-19 Initiated
Piper Jaffray
Neutral
$65
Feb-11-19 Resumed
Stifel
Buy
$71
Dec-19-18 Upgrade
Citigroup
Neutral → Buy
Aug-08-17 Reiterated
Stifel
Buy
$38 → $80
Aug-08-17 Reiterated
Leerink Partners
Outperform
$52 → $82
Jul-21-17 Downgrade
Goldman
Buy → Neutral
Jul-11-17 Initiated
Jefferies
Buy
Feb-11-16 Upgrade
Credit Suisse
Neutral → Outperform
$40
Jan-21-16 Initiated
Credit Suisse
Neutral
Apr-19-21 11:17PM
11:03PM
08:27PM
07:03PM
06:51PM
05:16PM
02:58PM
01:25PM
01:10PM
01:00PM
12:15PM
11:00AM
11:00AM
10:05AM
09:08AM
07:40AM
06:30AM
12:40AM
Apr-17-21 03:49PM
09:00AM
Apr-16-21 10:50PM
08:00PM
07:02PM
06:42PM
05:08PM
03:03PM
01:30PM
12:00PM
11:00AM
10:02AM
09:13AM
07:59AM
06:30AM
06:30AM
Apr-15-21 10:05PM
07:33PM
07:12PM
07:00PM
05:40PM
04:25PM
04:00PM
02:31PM
02:15PM
02:11PM
01:45PM
01:44PM
12:45PM
11:41AM
11:12AM
11:00AM
10:00AM
07:00AM
06:30AM
Apr-14-21 11:29PM
09:00PM
07:10PM
06:31PM
05:00PM
04:32PM
04:25PM
03:30PM
02:58PM
02:50PM
02:07PM
01:33PM
12:04PM
11:50AM
11:00AM
10:25AM
09:39AM
09:30AM
06:30AM
Apr-13-21 09:00PM
09:00PM
08:37PM
08:16PM
07:24PM
06:43PM
05:48PM
05:44PM
05:00PM
04:20PM
03:55PM
03:05PM
03:00PM
02:52PM
02:14PM
11:40AM
11:00AM
09:55AM
08:59AM
Apr-12-21 03:54PM
10:05AM
07:00AM
Apr-11-21 11:45PM
Apr-09-21 07:06PM
01:51PM
10:50AM
Apr-08-21 09:00PM
07:50PM
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KEARNS THOMAS F JR Director Mar 11 Option Exercise 3.50 18,000 63,000 166,164 Mar 15 06:22 PM KEARNS THOMAS F JR Director Mar 11 Sale 35.02 18,000 630,360 148,164 Mar 15 06:22 PM Kurkijarvi Kalevi Director Feb 17 Option Exercise 28.65 6,000 171,900 39,100 Feb 19 07:10 PM Kurkijarvi Kalevi Director Feb 17 Sale 52.40 6,000 314,383 33,100 Feb 19 07:10 PM Kurkijarvi Kalevi Director Jan 19 Option Exercise 19.05 6,000 114,300 39,100 Jan 21 07:24 PM Kurkijarvi Kalevi Director Jan 19 Sale 43.38 6,000 260,280 33,100 Jan 21 07:24 PM Kurkijarvi Kalevi Director Jan 14 Option Exercise 19.05 5,999 114,281 39,099 Jan 15 08:02 PM Kurkijarvi Kalevi Director Jan 14 Sale 40.04 5,999 240,200 33,100 Jan 15 08:02 PM Schoeneck James A Director Jan 04 Option Exercise 9.78 6,000 58,650 15,400 Jan 06 07:08 PM Kurkijarvi Kalevi Director Dec 28 Option Exercise 18.34 6,001 110,059 39,101 Dec 30 06:07 PM Kurkijarvi Kalevi Director Dec 28 Sale 40.40 6,001 242,455 33,100 Dec 30 06:07 PM Yu K Peony Chief Medical Officer Dec 16 Sale 41.61 3,350 139,394 192,292 Dec 17 07:06 PM Cotroneo Pat SVP, Finance and CFO Dec 15 Sale 43.60 3,068 133,765 266,144 Dec 17 07:04 PM Kouchakji Elias SVP, Clinical Dev, Drug Safety Nov 17 Option Exercise 14.57 7,082 103,220 134,495 Nov 19 04:52 PM Yu K Peony Chief Medical Officer Sep 16 Sale 44.01 3,351 147,478 198,934 Sep 18 05:19 PM Cotroneo Pat SVP, Finance and CFO Sep 15 Sale 43.63 3,070 133,944 272,226 Sep 17 06:03 PM Cotroneo Pat SVP, Finance and CFO Sep 03 Option Exercise 23.30 15,004 349,582 293,314 Sep 04 04:30 PM Yu K Peony Chief Medical Officer Sep 03 Option Exercise 18.00 10,000 180,000 215,576 Sep 04 04:33 PM Yu K Peony Chief Medical Officer Sep 03 Sale 50.89 10,000 508,900 205,576 Sep 04 04:33 PM Cotroneo Pat SVP, Finance and CFO Sep 03 Sale 50.91 15,004 763,854 278,310 Sep 04 04:30 PM Schoeneck James A Director Aug 20 Option Exercise 5.95 6,000 35,700 15,400 Aug 21 05:58 PM Cotroneo Pat SVP, Finance and CFO Aug 11 Option Exercise 18.72 7,250 135,712 278,310 Aug 11 04:34 PM Cotroneo Pat SVP, Finance and CFO Aug 07 Option Exercise 19.39 22,554 437,322 293,614 Aug 11 04:34 PM Cotroneo Pat SVP, Finance and CFO Aug 07 Sale 48.00 22,554 1,082,592 271,060 Aug 11 04:34 PM Yu K Peony Chief Medical Officer Jul 24 Sale 42.35 3,351 141,915 205,576 Jul 28 07:33 PM Cotroneo Pat SVP, Finance and CFO Jun 16 Sale 39.68 3,928 155,863 271,060 Jun 18 06:35 PM Conterno Enrique A Chief Executive Officer Jun 11 Buy 35.28 19,800 698,599 27,800 Jun 12 06:59 AM Conterno Enrique A Chief Executive Officer Jun 10 Buy 36.29 8,000 290,282 8,000 Jun 12 06:59 AM Rosenkranz Roberto Pedro Director Jun 09 Option Exercise 23.85 24,000 572,400 96,100 Jun 11 09:22 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite